echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Weekly trend of consistency evaluation: over evaluated enterprises gradually over compete

    Weekly trend of consistency evaluation: over evaluated enterprises gradually over compete

    • Last Update: 2019-07-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    As of July 11th, a total of 1263 acceptance numbers (373 varieties of 377 enterprises, according to the supplementary application, the same below) have been accepted by CDE, of which 222 (96 varieties) have passed the acceptance number Since 2019, after the peak declaration and approval of consistency evaluation in January, the pace has gradually slowed down In the past June, only 51 acceptance numbers have been undertaken and 11 acceptance numbers have passed; in July, it will be inevitable to catch up with and surpass June, and 56 acceptance numbers of consistency evaluation drugs have been undertaken by CDE by the 11th day before the deadline Source of data chart: this week (July 4 to July 11), the database of generic drug consistency evaluation and analysis system of pharmaceutical intelligence data Enterprise Edition continued to promote the consistency evaluation work, and 5 varieties were approved The past evaluation is about to be completed, 23 varieties were undertaken, and injections were filed See more details with the editor 1.5 over evaluation of varieties and continuous competition After the approval of acceptance No 6 (5 varieties) this week, metformin hydrochloride tablets of Shenzhen Zoomlion Pharmaceutical Co., Ltd., acetaminophen tablets of Hebei Jiheng Pharmaceutical Co., Ltd and montmorillonite powder of Harbin Pharmaceutical Co., Ltd were in the state of "certificate preparation completed - to be approved"; zuoxitirizin hydrochloride tablets of Suzhou Dongrui, Hangzhou Minsheng Pharmaceutical Co., Ltd and isoniazid tablets of Shenyang Hongqi Pharmaceutical Co., Ltd were in the state of "issued", which was announced by the waiting officials Good news It is worth mentioning in this week's detailed table of the review and approval of consistency evaluation that except for the fact that there are not three full members of paracetamol tablets, the other four varieties of enterprises that have been evaluated have exceeded their quota It can be seen that the competition is fierce and all enterprises are competing Among them, metformin hydrochloride tablets and montmorillonite powder have been evaluated by 5 enterprises, isoniazid tablets have been evaluated by 4 enterprises, and levocetirizine hydrochloride tablets have also been evaluated by 3 enterprises In addition, in addition to the approval of acetaminophen tablets by Hebei Jiheng Pharmaceutical Co., Ltd this week, the product of Tianjin Shike Pharmaceutical Co., Ltd in China and the United States last week has also been in the "issued" state We will wait and see who will take the top three places and enjoy the policy dividend first 2 45 acceptance numbers were undertaken, and one third of them were collected into the new 45 acceptance numbers of CDE this week, involving 23 varieties, of which 50% were the first accepted varieties (see the table at the end of the article for details) It is worth noting that this week's injection consistency evaluation was again filed, accounting for 71.11%, up to 32 acceptance numbers (12 varieties), and Qilu pharmaceutical, Zhengda Tianqing, Yangzijiang pharmaceutical, Sinopharm Ouyi, humanwell pharmaceutical and other heavyweight varieties were listed one after another Details of application and acceptance of consistency assessment injection this week It has to be mentioned that Zhengda Tianqing ' Early diagnosis and treatment of lesions The preparation of disodium gadolinate has attracted the attention of the industry due to its advantages of accurate effect, convenient use and controllable side effects In June, we just obtained the production approval document, which is the first generic medicine in China Now, we are working hard to accept the application of consistency evaluation We will take the lead again to consolidate the dominant position of Zhengda Tianqing in the field of liver health In addition, Qidu pharmaceutical industry in Shandong Province became another bright spot this week If not, it will be a surprise A total of 17 standard drugs (4 varieties) have been applied for conformity assessment and accepted All of them are injections, including tropisetron hydrochloride injection, glucose sodium chloride injection, sodium chloride injection and glucose injection It is worth mentioning that according to the database of generic drug consistency evaluation and analysis system of pharmaceutical intelligence data Enterprise Edition, up to now, there are 19 acceptance numbers and 5 varieties in Shandong Qidu pharmaceutical industry consistency evaluation application, and the previously applied acyclovir tablets have been evaluated at the beginning of this year According to the acceptance number, Shandong Qidu Pharmaceutical Co., Ltd has passed the test all the way and entered the top 10 enterprise of consistency evaluation application, which is in line with Hunan Kelun Pharmaceutical Co., Ltd Data source: Pharmaceutical intelligence data enterprise version generic drug consistency evaluation and analysis system database note: the above statistics are only calculated by individual companies, no consolidation of subsidiaries and parent companies Annex: details of this week's consistency evaluation application acceptance
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.